![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Alun McCarthy is President and CEO of PGXIS Ltd, and Chief Scientific officer of CytoPathfinder, Inc. PGXIS is a UK-based company that has developed innovative technology to analyze large, complex genomic data sets. This approach, called Taxonomy3, has a number of benefits over conventional analysis methods. These include: more statistical power to find associations; the ability to identify gene–gene interactions; greater predictive power; and integration of different data types in a single multivariate analysis.
Disclaimer
The opinions expressed in this article are those of the interviewee and do not necessarily reflect the views of Future Medicine Ltd.
Financial & competing interests disclosure
A McCarthy is an employee of PGXIS Ltd. A McCarthy has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.